

DIN EN ISO 14155:2021-05 (E)

Clinical investigation of medical devices for human subjects - Good clinical practice (ISO 14155:2020)

| Contents | | Page |
|---|---|-------------|
| European foreword | | 5 |
| Annex ZA (informative) Relationship between this European Standard and the essential requirements of Directive 93/42/EEC [OJ L 169] aimed to be covered | | 7 |
| Annex ZB (informative) Relationship between this European Standard and the essential requirements of Directive 90/385/EEC [OJ L 189] aimed to be covered | | 9 |
| Foreword | | 11 |
| 1 | Scope | 12 |
| 2 | Normative references | 12 |
| 3 | Terms and definitions | 12 |
| 4 | Summary of good clinical practice (GCP) principles | 20 |
| 5 | Ethical considerations | 21 |
| 5.1 | General..... | 21 |
| 5.2 | Improper influence or inducement..... | 21 |
| 5.3 | Compensation and additional health care..... | 21 |
| 5.4 | Registration in publicly accessible database..... | 22 |
| 5.5 | Responsibilities..... | 22 |
| 5.6 | Communication with the ethics committee (EC)..... | 22 |
| 5.6.1 | General..... | 22 |
| 5.6.2 | Initial EC submission..... | 22 |
| 5.6.3 | Information to be obtained from the EC..... | 23 |
| 5.6.4 | Continuing communication with the EC..... | 23 |
| 5.6.5 | Continuing information to be obtained from the EC..... | 23 |
| 5.7 | Vulnerable populations..... | 23 |
| 5.8 | Informed consent..... | 24 |
| 5.8.1 | General..... | 24 |
| 5.8.2 | Process of obtaining informed consent..... | 24 |
| 5.8.3 | Special circumstances for informed consent..... | 25 |
| 5.8.4 | Information to be provided to the subject..... | 26 |
| 5.8.5 | Informed consent signature..... | 28 |
| 5.8.6 | New information..... | 28 |
| 6 | Clinical investigation planning | 28 |
| 6.1 | General..... | 28 |
| 6.2 | Risk management..... | 29 |
| 6.2.1 | General..... | 29 |
| 6.2.2 | Investigational device including clinical procedure risks and their disclosure..... | 29 |
| 6.2.3 | Clinical investigation process..... | 29 |
| 6.3 | Justification for the design of the clinical investigation..... | 30 |
| 6.4 | Clinical investigation plan (CIP)..... | 30 |
| 6.5 | Investigator's brochure (IB)..... | 30 |
| 6.6 | Case report forms (CRFs)..... | 31 |
| 6.7 | Monitoring plan..... | 31 |
| 6.8 | Investigation site selection..... | 32 |
| 6.9 | Agreement(s)..... | 32 |
| 6.10 | Labelling..... | 32 |
| 6.11 | Data monitoring committee (DMC)..... | 32 |

| | | |
|-----------|--|-----------|
| 7 | Clinical investigation conduct | 33 |
| 7.1 | General | 33 |
| 7.2 | Investigation site initiation | 33 |
| 7.3 | Investigation site monitoring | 33 |
| 7.4 | Adverse events and device deficiencies | 33 |
| | 7.4.1 Signals requiring immediate action | 33 |
| | 7.4.2 Adverse events | 34 |
| | 7.4.3 Device deficiencies | 34 |
| | 7.4.4 Risk assessment process for potentially unacceptable risks | 34 |
| 7.5 | Clinical investigation documents and documentation | 35 |
| | 7.5.1 Amendments | 35 |
| | 7.5.2 Subject identification log | 35 |
| | 7.5.3 Source documents | 36 |
| 7.6 | Additional members of the investigation site team | 36 |
| 7.7 | Subject privacy and confidentiality of data | 36 |
| 7.8 | Document and data control | 36 |
| | 7.8.1 Traceability of documents and data | 36 |
| | 7.8.2 Recording of data | 36 |
| | 7.8.3 Electronic clinical data systems | 37 |
| 7.9 | Investigational device accountability | 38 |
| 7.10 | Accounting for subjects | 38 |
| 7.11 | Auditing | 38 |
| 8 | Suspension, termination, and close-out of the clinical investigation | 39 |
| 8.1 | Completion of the clinical investigation | 39 |
| 8.2 | Suspension or premature termination of the clinical investigation | 39 |
| | 8.2.1 Procedure for suspension or premature termination | 39 |
| | 8.2.2 Procedure for resuming the clinical investigation after temporary suspension | 40 |
| 8.3 | Routine close-out | 40 |
| 8.4 | Clinical investigation report | 41 |
| 8.5 | Risk assessment and conclusions | 41 |
| 8.6 | Document retention | 42 |
| 9 | Responsibilities of the sponsor | 42 |
| 9.1 | Clinical quality management | 42 |
| 9.2 | Clinical investigation planning and conduct | 42 |
| | 9.2.1 Selection and training of clinical personnel | 42 |
| | 9.2.2 Preparation of documents and materials | 43 |
| | 9.2.3 Conduct of clinical investigation | 44 |
| | 9.2.4 Monitoring | 44 |
| | 9.2.5 Safety evaluation and reporting | 47 |
| | 9.2.6 Clinical investigation close-out | 48 |
| 9.3 | Outsourcing of duties and functions | 48 |
| 9.4 | Communication with regulatory authorities | 48 |
| 10 | Responsibilities of the principal investigator | 49 |
| 10.1 | General | 49 |
| 10.2 | Qualification of the principal investigator | 49 |
| 10.3 | Qualification of investigation site | 49 |
| 10.4 | Communication with the EC | 49 |
| 10.5 | Informed consent process | 50 |
| 10.6 | Compliance with the CIP | 50 |
| 10.7 | Medical care of subjects | 51 |
| 10.8 | Safety reporting | 52 |

| | |
|--|-----------|
| Annex A (normative) Clinical investigation plan (CIP) | 53 |
| Annex B (normative) Investigator's brochure (IB) | 62 |
| Annex C (informative) Case report forms (CRFs) | 65 |
| Annex D (normative) Clinical investigation report | 67 |
| Annex E (informative) Essential clinical investigation documents | 72 |
| Annex F (informative) Adverse event categorization | 79 |
| Annex G (informative) EC responsibilities | 81 |
| Annex H (informative) Application of ISO 14971 to clinical investigations | 85 |
| Annex I (informative) Clinical development stages | 86 |
| Annex J (informative) Clinical investigation audits | 91 |
| Bibliography | 94 |